Radiant Biotherapeutics to Present Novel Multabody Technology for Cancer Immunotherapy at SITC 2025
Key Insights
Radiant Biotherapeutics (search) will present data on its proprietary Multabody (search) technology at the Society for Immunotherapy of Cancer 40th Annual Meeting in November 2025.
The company's Multabody (search) platform addresses limitations of current multi-specific antibodies by providing superior binding strength, precise tunability, and exceptional therapeutic breadth within a single engineered molecule.
The technology leverages apoferritin scaffolding and sophisticated protein engineering to create antibodies with therapeutic potential across cancer, autoimmune, and infectious diseases including HIV (search).
Radiant Biotherapeutics (search) announced it will present data on its breakthrough Multabody (search) technology at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5-9, 2025 in National Harbor, MD. The Toronto-based biotechnology company is advancing a novel antibody approach designed to treat cancer, autoimmune and infectious diseases.
Addressing Multi-Specific Antibody Limitations
Current multi-specific antibodies have shown promise as targeted drugs with the potential for simultaneous binding of two or more antigens or epitopes. However, inherent structural limitations often prevent optimal therapeutic outcomes for complex diseases due to suboptimal binding affinity and specificity challenges.
Radiant's proprietary Multabody (search) technology addresses these limitations by uniquely harnessing natural biological mechanisms to engage multiple disease targets with superior binding strength, precise tunability, and exceptional therapeutic breadth—all within a single engineered molecule. This breakthrough approach is particularly transformative for treating cancer, autoimmune, and infectious diseases, where the Multabody technology can direct immune cells to destroy tumors, block multiple disease pathways, or maintain therapeutic efficacy even as pathogens mutate.
Platform Technology and Manufacturing
The company's proprietary platform leverages apoferritin scaffolding and sophisticated protein engineering to create antibodies with unprecedented therapeutic potential across cancer, autoimmune and infectious diseases, including HIV (search). The platform is compatible with standard antibody manufacturing processes, bringing flexibility, modularity and scalability.
SITC Presentation Details
The poster presentation, titled "Multabodies: A next-generation approach for cancer immunotherapy and 4-1BB (search) agonist therapy," will be presented by Joanne Hulme, Ph.D., Chief Scientific Officer at Radiant Biotherapeutics (search). The presentation is scheduled for Tuesday, November 4, 2025, during the "Immune stimulants and immune modulators" session and carries abstract number 847.
All posters will be available on the virtual meeting platform beginning November 4, 2025, at 9 AM ET, with abstract titles currently available on the SITC 2025 Abstracts webpage.